R&D- MEDICAL: BIOMEDICAL (BASIC RESEARCH)

在美国每年有约20，000例胶质母细胞瘤，中位生存期只有15个月提出了两种技术的整合以创建用于胶质母细胞瘤的优化溶瘤病毒。由此产生的病毒具有三重武装：（1）它具有临床证明的机制和增强的逃避免疫系统的能力;（2）它破坏肿瘤中胶质母细胞瘤细胞之间的物理屏障，增强病毒传播;（3）它表达GM-CSF以增强抗癌免疫力。在这项工作结束时，将确定先导病毒是否具有治疗胶质母细胞瘤的潜力。下一步将是通过必要的临床前研究，向FDA提交IND并开始临床研究。胶质母细胞瘤的市场估计为4.49亿美元，为成功开发新疗法提供了巨大的优势。胶质母细胞瘤的预后非常差，迫切需要新的治疗方法。拟开发的治疗方法可以提高这些患者的生存率和生活质量。

There are ~20,000 cases per year of glioblastoma in the U.S., and median survival time is only 15 months. The integration of two technologies to create an optimized oncolytic virus for glioblastoma is proposed. The resulting virus is triply armed: (1) it has a clinically proven mechanism and enhanced abilities to evade the immune system; (2) it disrupts the physical barrier between glioblastoma cells in a tumor, enhancing viral spread; (3) it expresses GM-CSF to enhance anti-cancer immunity. At the end of this work, it will be determined if the lead virus has potential in the treatment of glioblastoma. The next steps would be to move it through the necessary preclinical studies required to file an IND with the FDA and begin clinical studies. The market for glioblastoma is estimated at $449M, providing significant upside to the successful development of a new treatment. Glioblastoma has a very poor prognosis, and new therapies are desperately needed. The treatment proposed to be developed could enhance survival and quality of life for these patients.